Adaptimmune Therapeutics plc Stock News

A mix of marketwide headwinds and company-specific events weighed on these three biotech stocks in November.

State Street Corp decreased its position in Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 36.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 259,582 shares of the biotechnology companys stock after selling 147,905 shares during the period. State Street Corp owned 0.17% of []

Cubist Systematic Strategies LLC grew its holdings in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 135.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,899 shares of the biotechnology companys stock after purchasing an additional 5,699 shares during the period. []

Investor sentiment has turned against this promising cell therapy company.

Investor sentiment has turned against this promising cell therapy company.

During the last session, Adaptimmune Therapeutics plc (NASDAQ:ADAP)s traded shares were 0.32 million, with the beta value of the company hitting 1.93. At the end of the trading day, the stocks price was $4.07, reflecting an intraday loss of -4.91% or -$0.21. The 52-week high for the ADAP share is $7.34, that puts it down Does Adaptimmune Therapeutics plc (NASDAQ: ADAP) Still Look Attractive After A -2.16% Selloff Last Week? Read More »

Squarepoint Ops LLC lowered its stake in Adaptimmune Therapeutics plc (NASDAQ:ADAP) by 63.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,997 shares of the biotechnology companys stock after selling 24,216 shares during the period. Squarepoint Ops LLCs holdings []

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk. Risk & Volatility BioCryst Pharmaceuticals has a beta of 2.51, suggesting that its share price is []

Gene Therapy Market Report 2021-2028 includes a comprehensive analysis of the present Market. The report starts with the basic Gene Therapy industry overview and then goes into each and every detail. Gene Therapy Market Report contains in depth information major manufacturers,

Equities research analysts expect that Adaptimmune Therapeutics plc (NASDAQ:ADAP) will post $80.25 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Adaptimmune Therapeutics earnings. The lowest sales estimate is $1.50 million and the highest is $159.00 million. Adaptimmune Therapeutics reported sales of $1.50 million in the same []

Adaptimmune Therapeutics and Agenus are having a tough go of it in the final quarter of 2021.

Wall Street brokerages expect that Adaptimmune Therapeutics plc (NASDAQ:ADAP) will announce $0.23 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Adaptimmune Therapeutics earnings. The highest EPS estimate is $0.71 and the lowest is ($0.26). Adaptimmune Therapeutics posted earnings per share of ($0.24) during the same []

Los Angeles, USA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Promising Treatment for Advanced Hepatocellular Carcinoma Enters Clinical Trials | DelveInsight There are a plethora of companies developing therapies to treat Advanced Hepatocellular Carcinoma. CStone Pharmaceuticals has its drug candidate in the most advanced stage (Phase III). DelveInsight''s " Advanced Hepatocellular Carcinoma Pipeline Insight " report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Advanced Hepatocellular Carcinoma pipeline landscapes. It comprises Advanced Hepatocellular Carcinoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Advanced Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Advanced Hepatocellular Carcinoma pipeline products. Some of the key takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report Major companies such as CStone Pharmaceuticals, Akesobio, Chia Tai Tianqing Pharmaceutical Group, Yiviva Inc., BeiGene, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Carsgen Therapeutics, Ltd., Jiangsu Alphamab Biopharmaceuticals, Sunshine Lake Pharma Co., Ltd., AVEO Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd., Sinocelltech Ltd., LTD, Eureka Therapeutics Inc., Taizhou Hanzhong biomedical co.

Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q3 2021 Results - Earnings Call Transcript

These two small-cap cancer companies would be a perfect fit for Pfizer.